Welcome to our dedicated page for Stryker Corporation news (Ticker: $SYK), a resource for investors and traders seeking the latest updates and insights on Stryker Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Stryker Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Stryker Corporation's position in the market.
Stryker (NYSE: SYK) successfully completed the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology. The system is designed for efficient and accurate implementation, with positive outcomes in end-stage ankle arthritis patients. The company aims to enhance collaboration with surgeons through innovation and commitment to research.
Stryker reported strong operating results for the first quarter of 2024, with a 9.7% increase in net sales to $5.2 billion, 10% organic net sales growth, and a 33.1% increase in reported EPS. The company's MedSurg and Neurotechnology segment saw a 11.5% increase in net sales, while Orthopaedics and Spine segment reported a 7.5% increase. Adjusted operating income margin increased to 21.9%, and adjusted EPS rose by 16.8%. Stryker expects full year 2024 organic net sales growth in the range of 8.5% to 9.5%, with adjusted net earnings per diluted share projected to be between $11.85 to $12.05.
